| Revenue growth | FY26 grew 12.8% YoY; US/North America up 24%. |
|---|---|
| Margins | EBITDA margin improved to 22.8% in Q4FY26. |
| Order book | Strong order book execution; momentum expected to continue. |
| Demand visibility | Sustained momentum in US; peak-season demand in Australia. |
| Management confidence | High, successfully delivered on guidance for FY26. |
Growth
FY26 revenue grew 12.8% YoY; PAT up 9.8%. Q4FY26 revenue grew 20.8% YoY with EBITDA margin expanding to 22.8%.
Outlook
Major capex cycle nearly complete. Plans to launch 20-25 new products annually; 200+ products in 4-year filing pipeline.
Risks
Monitoring emerging input cost pressures and ongoing geopolitical tensions affecting global logistics and RoW market demand.
Earnings Call filed with NSE, NSE: MARKSANS. Summary written with AI assistance from the document.
Marksans Pharma Ltd: key numbers
- Share price
- ₹325.00
- Market cap
- ₹14,728 Cr
- Revenue (annual)
- ₹2,951 Cr
- Net profit (annual)
- ₹417.9 Cr
- P/E (TTM)
- 28.5×Sector 47.4×
- Promoter holding
- 43.87%+0.00% QoQ
- FII holding
- 17.47%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Marksans Pharma Ltd
All →Marksans Pharma Promoter Selling (Off-Market)
Director Sandra Saldanha gifted 2,28,273 shares of Marksans Pharma Ltd to her daughters in an off-market transaction. This internal transfer reallocates promoter-group equity holdings.
Marksans Pharma Other Announcement
Marksans Pharma intimated shareholders about SEBI's extended special window (Feb 2026–Feb 2027) for re-lodgement of pre-April-2019 physical share transfer deeds. No new business, capital, or operational event is disclosed.
Marksans Pharma Annual General Meeting
Marksans Pharma Limited conducted its 34th Annual General Meeting on August 27, 2026. Shareholders considered the adoption of FY2025-26 financial statements and a dividend of Rs. 0.90 per share.
Marksans Pharma Other Announcement
Marksans Pharma Ltd. has received an ESG score of 56 from Crisil ESG Ratings & Analytics Ltd for Fiscal 2026.
Marksans Pharma Investor Presentation: Key Takeaways
Strong Q1FY27 performance driven by European growth and acquisitions. Marksans achieved highest-ever quarterly EBITDA and PAT, while crossing INR1,000 Cr cash balance.
- Call
- Guides 20% growth
Marksans Pharma Q1 FY27 Results: Net Profit ₹159.4 Cr, Up 173.9% YoY
Marksans Pharma Ltd reported revenue from operations of ₹840.8 Cr (+35.6% YoY) and net profit of ₹159.4 Cr (+173.9% YoY) for Q1 FY27.
- Key figure
- Net profit ₹159.4 Cr · +173.9% YoY